APA (7th ed.) Citation

Shin, S. J., O'Sullivan Coyne, G., Streicher, H., Takebe, N., Bruns, A., Sharon, E., . . . Chen, A. P. (2022). Abstract CT147: Phase 1 study of recombinant interleukin 15 (rhIL-15) in combination with checkpoint inhibitors nivolumab and ipilimumab in subjects with refractory cancers. Cancer research (Chicago, Ill.), 82(12_Supplement), CT147. https://doi.org/10.1158/1538-7445.AM2022-CT147

Chicago Style (17th ed.) Citation

Shin, Sarah J., et al. "Abstract CT147: Phase 1 Study of Recombinant Interleukin 15 (rhIL-15) in Combination with Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers." Cancer Research (Chicago, Ill.) 82, no. 12_Supplement (2022): CT147. https://doi.org/10.1158/1538-7445.AM2022-CT147.

MLA (9th ed.) Citation

Shin, Sarah J., et al. "Abstract CT147: Phase 1 Study of Recombinant Interleukin 15 (rhIL-15) in Combination with Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers." Cancer Research (Chicago, Ill.), vol. 82, no. 12_Supplement, 2022, p. CT147, https://doi.org/10.1158/1538-7445.AM2022-CT147.